Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses outcomes of the tumor agnostic RAGNAR trial (NCT04083976), where erdafitinib was prescribed to patients with an FGFR3 alteration. The mutation frequency in patients was not sufficient to sustain randomized clinical trials. Over 200 patients were enrolled, where objective response rates (ORR) were especially promising inpatients with salivary duct tumors, endometrial carcinomas, and cholangiocarcinoma. These findings highlights the efficacy of FGF-targeted therapy using erdafitinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
